- Home
- SCPQ vs ANTX Comparison
SCPQ vs ANTX Comparison
Compare SCPQ & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCPQ | ANTX |
|---|---|---|
| Founded | 2025 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.5M | 135.4M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | SCPQ | ANTX |
|---|---|---|
| Price | $9.90 | $3.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 842.0 | ★ 3.5M |
| Earning Date | 01-01-0001 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.86 | $1.00 |
| 52 Week High | $9.95 | $6.91 |
Technical Indicators
Market Signals| Indicator | SCPQ | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 53.19 |
| Support Level | N/A | $1.05 |
| Resistance Level | N/A | $6.91 |
| Average True Range (ATR) | 0.00 | 0.60 |
| MACD | 0.00 | -0.20 |
| Stochastic Oscillator | 0.00 | 7.35 |
Price Performance
Historical ComparisonAbout SCPQ Social Commerce Partners Corporation Class A Ordinary Shares
Social Commerce Partners Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.